UnknownPhase 4

Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy

China89 participantsStarted 2021-06-16

Plain-language summary

Biochemical response of primary biliary cholangitis-autoimmune hepatitis overlap syndrome induced by mycophenolate mofetil versus cyclosporin A

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. The presence of hepatitis A, B, C, D, or E virus infection;
✕. Patients with presence of serious decompensated cirrhosis;
✕. Patients have a history of glucocorticoid or immunosuppressant medication before enrollment;
✕. Liver damage caused by other reasons: such as primary sclerosing cholangitis, non-alcoholic steatohepatitis, drug induced liver disease or Wilson's disease.
✕. Pregnant and breeding women and women of childbearing age in need of reproduction
✕. Severe disorders of other vital organs, such as severe heart failure, cancer;
✕. Patients with presence of renal insufficiency;
✕. Parenteral administration of blood or blood products within 6 months before screening;

Biochemical remission

Timeframe: up to 6 months

NCT IDNCT04376528

SponsorWest China Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-12-30

Xiaoli Fan, Master degree